vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and PEGASYSTEMS INC (PEGA). Click either name above to swap in a different company.
PEGASYSTEMS INC is the larger business by last-quarter revenue ($430.0M vs $284.0M, roughly 1.5× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 7.6%, a 88.7% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -9.6%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 10.7%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Pegasystems Inc. (Pega) is a global software company based in Waltham, Massachusetts, in the United States, and founded in 1983. The company has been publicly traded since 1996 as PEGA (NASDAQ). Pega is a low-code platform for workflow automation and generative AI-powered decision-making for businesses.
ACAD vs PEGA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $430.0M |
| Net Profit | $273.6M | $32.8M |
| Gross Margin | 90.8% | 75.2% |
| Operating Margin | 6.1% | 8.6% |
| Net Margin | 96.3% | 7.6% |
| Revenue YoY | 9.4% | -9.6% |
| Net Profit YoY | 90.3% | — |
| EPS (diluted) | $1.61 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $430.0M | ||
| Q4 25 | $284.0M | $504.3M | ||
| Q3 25 | $278.6M | $381.4M | ||
| Q2 25 | $264.6M | $384.5M | ||
| Q1 25 | $244.3M | $475.6M | ||
| Q4 24 | $259.6M | $490.8M | ||
| Q3 24 | $250.4M | $325.1M | ||
| Q2 24 | $242.0M | $351.2M |
| Q1 26 | — | $32.8M | ||
| Q4 25 | $273.6M | $234.6M | ||
| Q3 25 | $71.8M | $43.4M | ||
| Q2 25 | $26.7M | $30.1M | ||
| Q1 25 | $19.0M | $85.4M | ||
| Q4 24 | $143.7M | $119.1M | ||
| Q3 24 | $32.8M | $-14.4M | ||
| Q2 24 | $33.4M | $6.6M |
| Q1 26 | — | 75.2% | ||
| Q4 25 | 90.8% | 79.5% | ||
| Q3 25 | 92.2% | 72.2% | ||
| Q2 25 | 92.2% | 71.5% | ||
| Q1 25 | 91.7% | 78.5% | ||
| Q4 24 | 91.6% | 79.1% | ||
| Q3 24 | 92.5% | 70.2% | ||
| Q2 24 | 92.5% | 72.4% |
| Q1 26 | — | 8.6% | ||
| Q4 25 | 6.1% | 20.7% | ||
| Q3 25 | 12.8% | 3.8% | ||
| Q2 25 | 12.2% | 4.5% | ||
| Q1 25 | 7.9% | 26.7% | ||
| Q4 24 | 59.1% | 29.1% | ||
| Q3 24 | 12.6% | -3.6% | ||
| Q2 24 | 12.6% | 3.7% |
| Q1 26 | — | 7.6% | ||
| Q4 25 | 96.3% | 46.5% | ||
| Q3 25 | 25.8% | 11.4% | ||
| Q2 25 | 10.1% | 7.8% | ||
| Q1 25 | 7.8% | 18.0% | ||
| Q4 24 | 55.4% | 24.3% | ||
| Q3 24 | 13.1% | -4.4% | ||
| Q2 24 | 13.8% | 1.9% |
| Q1 26 | — | $0.18 | ||
| Q4 25 | $1.61 | $0.81 | ||
| Q3 25 | $0.42 | $0.24 | ||
| Q2 25 | $0.16 | $0.17 | ||
| Q1 25 | $0.11 | $0.91 | ||
| Q4 24 | $0.86 | $1.35 | ||
| Q3 24 | $0.20 | $-0.17 | ||
| Q2 24 | $0.20 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $270.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $705.9M |
| Total Assets | $1.6B | $1.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $270.0M | ||
| Q4 25 | $177.7M | $425.8M | ||
| Q3 25 | $258.0M | $351.4M | ||
| Q2 25 | $253.6M | $411.6M | ||
| Q1 25 | $217.7M | $371.7M | ||
| Q4 24 | $319.6M | $740.0M | ||
| Q3 24 | $155.1M | $703.0M | ||
| Q2 24 | $177.1M | $665.1M |
| Q1 26 | — | $705.9M | ||
| Q4 25 | $1.2B | $787.4M | ||
| Q3 25 | $917.3M | $596.8M | ||
| Q2 25 | $822.4M | $624.5M | ||
| Q1 25 | $765.2M | $611.3M | ||
| Q4 24 | $732.8M | $585.5M | ||
| Q3 24 | $577.2M | $473.0M | ||
| Q2 24 | $516.7M | $435.4M |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $1.6B | $1.6B | ||
| Q3 25 | $1.3B | $1.3B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.1B | $1.3B | ||
| Q4 24 | $1.2B | $1.8B | ||
| Q3 24 | $976.9M | $1.6B | ||
| Q2 24 | $914.1M | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | $206.5M |
| FCF MarginFCF / Revenue | — | 48.0% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $494.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $158.4M | ||
| Q3 25 | $74.3M | $56.3M | ||
| Q2 25 | $64.0M | $86.3M | ||
| Q1 25 | $20.3M | $204.2M | ||
| Q4 24 | $40.4M | $95.2M | ||
| Q3 24 | $63.2M | $30.5M | ||
| Q2 24 | $25.0M | $40.1M |
| Q1 26 | — | $206.5M | ||
| Q4 25 | — | $152.4M | ||
| Q3 25 | $73.9M | $51.8M | ||
| Q2 25 | — | $84.1M | ||
| Q1 25 | — | $202.3M | ||
| Q4 24 | — | $92.4M | ||
| Q3 24 | $63.2M | $27.4M | ||
| Q2 24 | — | $38.8M |
| Q1 26 | — | 48.0% | ||
| Q4 25 | — | 30.2% | ||
| Q3 25 | 26.5% | 13.6% | ||
| Q2 25 | — | 21.9% | ||
| Q1 25 | — | 42.5% | ||
| Q4 24 | — | 18.8% | ||
| Q3 24 | 25.2% | 8.4% | ||
| Q2 24 | — | 11.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.2% | ||
| Q3 25 | 0.1% | 1.2% | ||
| Q2 25 | — | 0.6% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.6% | ||
| Q3 24 | 0.0% | 0.9% | ||
| Q2 24 | — | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 0.68× | ||
| Q3 25 | 1.03× | 1.30× | ||
| Q2 25 | 2.40× | 2.87× | ||
| Q1 25 | 1.07× | 2.39× | ||
| Q4 24 | 0.28× | 0.80× | ||
| Q3 24 | 1.93× | — | ||
| Q2 24 | 0.75× | 6.06× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
PEGA
| Pega Cloud | $205.0M | 48% |
| Subscription license | $94.9M | 22% |
| Maintenance | $75.3M | 18% |
| Consulting | $54.8M | 13% |
